1215678-43-5
1215678-43-5
Chemical Structure
Nilotinib-d3
- CAS No.: 1215678-43-5
- Formula:C28H19D3F3N7O
- Molecular Weight:532.53
IUPAC Name: 4-methyl-N-(3-(4-(methyl-d3)-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide
InChIKey: HHZIURLSWUIHRB-BMSJAHLVSA-N
SMILES: C(F)(F)(F)C=1C=C(C=C(NC(=O)C2=CC(NC=3N=C(C=CN3)C=4C=CC=NC4)=C(C)C=C2)C1)N5C=NC(C([2H])([2H])[2H])=C5
Biological Activity: Nilotinib-d3 is the deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nilotinib-d3 | Nilotinib-d3 is the deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nilotinib (Standard) | 99.97% | Nilotinib (Standard) is the analytical standard of Nilotinib. This product is intended for research and analytical applications. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nilotinib-d6 | 99.87% | Nilotinib-d6 is a deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nilotinib-13C,d3 | Nilotinib-13C,d3 is a deuterated labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nilotinib | 99.94% | Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20. [Content Brief]
